Trial Profile
Ranibizumab combined with photodynamic therapy for the treatment of advanced-stage exudative age-related macular degeneration
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 04 Apr 2018 New trial record